Molecular therapy for Myocardial Infarction: PPARδ improves myocardial function after myocardial infarction via up-regulation of PNUTS, 29/November/2016, 6.00 am

Natural product Life-span extension therapy: N(1), N(11)-Diethylnorspermine, a spermine analog, may increase life span by suppressing mTOR pathway, 28/November/2016, 11.13 pm
November 28, 2016
Natural product-derived anti-ageing therapy: 2,4,5-trihydroxybenzaldehyde (TDB), found in Geum japonicum and Polygonum cuspidatum (PC), also known as Japanese knotweed, increases NMN levels, decreases age-associated weight gain, augments energy metabolism, improves physical activity and insulin sensitivity, promotes healthy lipid profile, and improves eye function via down regulation of its target gene, 29/November/2015, 10.10 am
November 29, 2016
Show all

Introduction: What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-price-100cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: PPARδ improves myocardial function after myocardial infarction via  up-regulation of PNUTS


From Significance of the study to Public health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free drug.


From Research Findings to Therapeutic Opportunity

This study suggests a small molecule-based cardiac regeneration therapy. PPARδ (Peroxisome proliferator-activated receptor (PPAR) δ), by increasing the expression of its target gene, it may increase the expression of PNUTS. Thereby, it may: (1) inhibit DNA damage responses, (2) inhibit telomere shortening; and (3) promote cardiomyocyte survival/regeneration (figure 1).

ppard-increases-pnuts-expressionThus, by treating cardiac patients with PPARδ activators, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that “PPARδ or its activators or PPARδ activators plus any of the known drugs that prevent/improve myocardial infarction” can be used to improve myocardial function and prevent myocardial infarction. 


Details of the Research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed Mechanistic insights: How  does  PPARδ increase the expression of PNUTS?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100#

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web:http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L.,  Molecular therapy for Myocardial Infarction: PPARδ improves myocardial function after myocardial infarction via  up-regulation of PNUTS, 29/November/2016, 6.00 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.